Vir Biotechnology, Inc. Form 8-K (Sept. 16, 2020)

Summary

Form 8-K current report of Vir Biotechnology, Inc. dated September 16, 2020, filed under Item 8.01 (Other Events). It reports that on September 16, 2020 the company presented at the H.C. Wainwright 22nd Annual Global Investment Conference. A copy of the presentation is attached as Exhibit 99.1.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT
REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 16, 2020

Vir Biotechnology, Inc.

(Exact name of registrant as specified in its charter)

Delaware | 001-39083 | 81-2730369
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.)

499 Illinois Street, Suite 500

San Francisco, California 94158

(Address of principal executive offices, including zip code)

(415) 906-4324

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.0001 par value | VIR | Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐

Item 8.01 Other Events.

On September 16, 2020, Vir Biotechnology, Inc. presented at the H.C. Wainwright 22nd Annual Global Investment Conference. A copy of the
presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial
Statements and Exhibits.

(d) Exhibits

Exhibit Number | Description
99.1 | Presentation, dated September 16, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.

Vir Biotechnology, Inc.
Date: September 16, 2020 | By: | /s/ Howard Horn
Howard Horn Chief Financial
Officer

File and source

File

SEC_VIR_8-K_filed2020-09-16_0001193125-20-247168.htm

Size

16,713 bytes

SHA-256

e64a0c60ca22efe3036c3524fe1ddb7b3836f8aea675487be5072a6d7770d211

Our copy

SEC_VIR_8-K_filed2020-09-16_0001193125-20-247168.htm

Original

www.sec.gov

Exhibits

Exhibit 99.1: Vir Biotechnology, Inc., presentation at the H.C. Wainwright 22nd Annual Global Investment Conference, Sept. 16, 2020